Jeremy Skillington of Poolbeg Pharma: First time RSV drug candidates have been identified using AI
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Jeremy Skillington CEO of discusses how their cutting edge AI program, in collaboration OneThree Biotech, has identified RSV drug candidates, a first for the industry.
Highlights
Poolbeg Pharma , a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus ('RSV') artificial intelligence ('AI') Programme with OneThree Biotech, Inc.
Since initiating the collaboration in February 2022, Poolbeg's scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg's unique RSV human challenge trial data in order to identify disease-relevant biological pathways and potential drug targets. Based on those newly discovered drug targets, the collaboration has now identified a number of promising drug candidates to rapidly bring forward to lab-based validation to determine the full potential of these assets.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.